*Materials described herein are referenced from CDC.Gov

(click here for more information)


This rise in opioid overdose deaths can be outlined in three distinct waves:

  1. The first wave began with increased prescribing of opioids in the 1990s, with overdose deaths involving prescription opioids (natural and semi-synthetic opioids and methadone) increasing since at least 1999.

  2. The second wave began in 2010, with rapid increases in overdose deaths involving heroin.

  3. The third wave began in 2013, with significant increases in overdose deaths involving synthetic opioids – particularly those involving illicitly-manufactured fentanyl (IMF). The IMF market continues to change, and IMF can be found in combination with heroin, counterfeit pills, and cocaine. 

     The mission of CerSci Therapeutics is singular- pain relief from new drugs developed from understanding mechanisms which cause pain, and conquering resultant neuronal sensitization.  This mandate sets CerSci apart from other companies with analgesic products / programs.  Our research is supported by robust scientific data and backed by a team with synergistic expertise.  Our first drug will go into human clinical trials in 2018, we expect to receive FDA high-priority status and we will have a human readout in late 2018.  



Combatting the Opioid Overdose Epidemic


*Materials described herein are referenced from CDC.Gov

(click here for more information)


The CDC is committed to fighting the opioid overdose epidemic and supporting states and communities as they continue work to identify outbreaks, collect data, and respond to overdoses, and provide care to those in their communities.


The CDC’s Prevention for States and Data-Driven Prevention Initiative programmatic aims center around the enhancement of PDMPs within clinical and public health settings, insurer and community interventions, evaluation of state-level policies, and other innovative strategies that states can employ.


The CDC’s Enhanced State Opioid Overdose Surveillance program aims to support and build the capacity of states to monitor the epidemic by improving the timeliness and quality of surveillance data focusing on both fatal and nonfatal opioid overdose.

it's time to live in a world with less pain.

  • Prevention/alleviation of tactile allodynia

  • Prevention/alleviation of thermal hyperalgesia

  • Prevention/alleviation of mechanical hypersensitivity in multiple painful diabetic neuropathy models 

  • Alleviation of allodynia in chemo-induced peripheral neuropathy models

  • Sustained relief upon single administration (day(s))

  • High oral bioavailability across species

  • Lack of tolerance

  • No sedation/motor impariment

  • No GI ulceration 

  • No genotoxicity signals

  • Clean CV profile and safety pharmacology profile (CNS, Respiratory)

  • No effects on core body temperature

Why we believe it's time for a new solution!

Understanding the Opioid Epidemic - Centers for Disease Control and Prevention (CDC)

Check out CerSci in the press right here!

     CerSci Therapeutics is taking a new approach to developing novel pain therapeutics.

Rather than concentrating on ion channel and GPCR targets, CerSci's science is focused on interrupting pathways that cause pain. 


Overview of Peroxynitrite & Peroxide with Respect to Pain


Reactive and powerful oxidants:

  • Peroxynitrite reacts with (electron-rich) aromatic residues to produce nitrated tyrosine residues

  • Peroxynitrite oxidizes thiol residues to nitrosothiols and can form disulfide bonds (i.e., cross-link residues within protein)

  • Hydrogen peroxide oxidizes reactive moieties found in small molecule metabolic products


--> Resultant downstream effects: aberrant, dysfunctional proteins; maintenance/perturbation of redox cycle protecting normal cell homeostasis


  • TRPA1 activation produces nitrotyrosine staining (a known marker of PN), which is attenuated by PN scavenger (Aubdool et al. British Journal of Pharmacology. 2016)

  • PN produces TRPA1 hyperexcitation via disulfide formation (Andersson et al. Journal of Biological Chemistry. 2015)

  • PN and H2O2 inhibit glyoxalase 1 (Antognelli et al. Free Radical Biology and Medicine. 2015)

  • Disruption of glutathione <-> disulfide equilibrium

  • Hydrogen peroxide is a co-factor in the peroxidase-mediated oxidation of glutathione. PN causes depletion in glutathione levels.

  • Nitrotyrosine staining correlates to opioid tolerance (PN decomposition catalyst attenuates nitrotyrosine staining and the development of tolerance) (Muscoli et al. J Clin Inv. 2007)

     CT-044, CerSci lead molecular asset undergoing IND-enabling studies, is a highly orally-bioavailable, peripherally-acting, non-metal-based Reactive Species Decomposition Accelerant (RSDAx). CT-044 has demonstrated efficacy across a battery of incisional, inflammatory, and neuropathic pain models with a clean animal safety package: